Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.55 |
| ▸ | YARS1 | P54577 | 2/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPY1R | P25929 | 1/20 | 0.48 |
| ▸ | NPY2R | P49146 | 1/20 | 0.48 |
| ▸ | NPY4R | P50391 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29571440 | 0.97 | SLC7A5 (0.58) | SLC7A5YARS1OPRD1ENPEPMEN1 | |
| SCHEMBL31121651 | 0.96 | ENPEP (0.54) | SLC7A5YARS1OPRD1ENPEPMEN1 | |
| SCHEMBL30712170 | 0.96 | ENPEP (0.54) | SLC7A5YARS1OPRD1ENPEPMEN1 | |
| SCHEMBL29630566 | 0.94 | OPRD1 (0.55) | OPRD1MME | |
| SCHEMBL30494285 | 0.94 | SLC7A5 (0.51) | SLC7A5YARS1OPRD1ENPEP | |
| SCHEMBL30123118 | 0.93 | OPRD1 (0.56) | OPRD1MME | |
| SCHEMBL29730651 | 0.93 | MME (0.52) | SLC7A5YARS1ENPEPMME | |
| SCHEMBL29839256 | 0.93 | OPRD1 (0.56) | OPRD1MME | |
| SCHEMBL29531959 | 0.93 | MME (0.58) | OPRD1MME | |
| SCHEMBL30149609 | 0.91 | ENPEP (0.53) | SLC7A5YARS1ENPEPMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011367-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | ENTRADA THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| US-20220177523-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | ENTRADA THERAPEUTICS, INC. | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011367-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | VIP, LNPEP, TAP1 | SLC7A5 42/4885YARS1 649/4885OPRD1 3314/4885 |
| US-20220177523-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | VIP, LNPEP, TAP1 | SLC7A5 42/4885YARS1 649/4885OPRD1 3314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.